Standard Chemoradiotherapy for Grade 3 Oligodendroglioma (IDH-mutant, 1p/19q-codeleted)
For grade 3 oligodendroglioma (IDH-mutant, 1p/19q-codeleted), the standard treatment is radiation therapy at 59.4 Gy in 33 fractions (five fractions per week) followed by adjuvant PCV chemotherapy for six cycles. 1
Radiation Therapy Protocol
The radiation dose is 59.4 Gy delivered in 33 fractions at 1.8 Gy per fraction, given five times per week. This regimen is based on the landmark EORTC 26951 trial and represents the standard approach for grade 3 oligodendrogliomas. 1
Chemotherapy Protocol: PCV Regimen
PCV remains the gold standard based on high-quality evidence from EORTC 26951 and RTOG 9402 trials showing significant survival benefits specifically in 1p/19q-codeleted tumors. 1
The PCV regimen consists of:
- Procarbazine: 60 mg/m² orally once daily on days 8-21
- Lomustine (CCNU): 110 mg/m² orally once on day 1
- Vincristine: 1.4 mg/m² IV once on days 8 and 29
Each cycle lasts 8 weeks, and patients receive a total of six cycles. 1
Alternative: Temozolomide
Temozolomide is a reasonable alternative to PCV when toxicity is a concern, though the evidence supporting its equivalence to PCV in this specific population is lower quality. 1
The temozolomide regimen:
- 150-200 mg/m² orally once daily on days 1-5
- Given every 4 weeks
- Maximum duration of 12 months
Critical Distinction from Lower-Grade Disease
The 2025 ASCO-SNO guideline update introduced vorasidenib for grade 2 oligodendrogliomas where treatment can be deferred, but this does not apply to grade 3 tumors. 2 Grade 3 oligodendrogliomas require immediate chemoradiotherapy given their more aggressive biology.
Evidence Supporting This Approach
The EORTC 26951 trial demonstrated that patients with 1p/19q-codeleted tumors achieved a median overall survival of 9.53 years with combined chemoradiotherapy. 1 The RTOG 9402 trial showed that PCV plus radiation doubled median survival compared to radiation alone in codeleted tumors (14.7 vs 7.3 years). 3
Both trials consistently showed that 1p/19q codeletion predicts exceptional benefit from PCV chemotherapy, making this molecular marker essential for treatment planning. 1 The survival benefit is specific to the addition of chemotherapy—radiation alone is insufficient.
Common Pitfalls to Avoid
Do not defer treatment in grade 3 oligodendrogliomas. Unlike grade 2 tumors where observation may be appropriate in select cases, grade 3 tumors require prompt initiation of chemoradiotherapy after maximal safe resection. 1
Do not substitute temozolomide without considering PCV first. While temozolomide is more convenient and better tolerated, PCV has the strongest evidence base for survival benefit in this specific molecular subtype. 1, 4 Reserve temozolomide for patients who cannot tolerate PCV due to toxicity concerns.
Ensure molecular confirmation before treatment. The 1p/19q codeletion status fundamentally determines treatment approach and prognosis—patients without codeletion have dramatically different outcomes and may require different management strategies. 1
Long-Term Monitoring Considerations
These patients have prolonged survival (median OS approaching 15 years with modern treatment), making long-term toxicity monitoring essential. 4, 3 However, concerns about radiation-induced neurotoxicity should not lead to omitting radiotherapy, as delaying radiation may be detrimental to overall survival. 5